NASDAQ: INTSIntensity Therapeutics Inc Stock
$3.86-0.14 (-3.5%)
Updated May 3, 2024
INTS Price
$3.86
Fair Value Price
$0.97
Market Cap
$52.92M
52 Week Low
$2.01
52 Week High
$11.44
P/E
-2.8x
P/B
4.02x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.54M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.31
Operating Cash Flow
-$7M
Beta
1.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INTS Overview
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INTS ($3.86) is overvalued by 296.03% relative to our estimate of its Fair Value price of $0.97 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INTS ($3.86) is not significantly undervalued (296.03%) relative to our estimate of its Fair Value price of $0.97 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INTS due diligence checks available for Premium users.
Be the first to know about important INTS news, forecast changes, insider trades & much more!
INTS News
Valuation
INTS fair value
Fair Value of INTS stock based on Discounted Cash Flow (DCF)
Price
$3.86
Fair Value
$0.97
Overvalued by
296.03%
INTS ($3.86) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INTS ($3.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INTS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.8x
Industry
6.05x
Market
35.94x
INTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.02x
Industry
6.01x
INTS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INTS's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
INTS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$17.3M
Liabilities
$4.1M
Debt to equity
0.31
INTS's short-term assets ($15.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INTS's short-term assets ($15.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$947.2k
Investing
$2.8M
Financing
-$12.2k
INTS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INTS vs Biotech Stocks
Intensity Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.